VEGF deficit is involved in endothelium dysfunction in preeclampsia

Abstract

This study examined the association of expression of vascular endothelial growth factor (VEGF), a promoter of angiogenesis, with endothelium dysfunction in preeclampsia. The level of VEGF protein and mRNA in the placenta and peripheral blood samples of 30 preeclampsia patients and 30 normotensive pregnant women was measured by immunohistochemistry, real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. VEGF expression in the human umbilical vein endothelial cells (HUVECs) was blocked by small interfering RNAs (siRNAs). The monolayer barrier function of HUVECs was determined by measuring the fluorescence intensity of BSA that crossed the HUVEC monolayers. The cell proliferation and cell-secreted nitric oxide (NO) level were detected by MTT method and nitrate reductase assay, respectively. The results showed that VEGF was expressed in the syncytiotrophoblasts and endothelial cells of vessels and capillaries in the placenta tissue. The serum level of VEGF in the preeclampsia patients was significantly decreased as compared with that in normal pregnant subjects, although VEGF mRNA expression in the placenta tissue of preeclampsia patients remained still high. Moreover, VEGF deficit could lead to endothelium cell dysfunction, and the administration of VEGF could protect endothelium cells from injury. It was concluded that lack of VEGF contributes to endothelium dysfunction, which may lead to the occurrence and development of preeclampsia.

Keywords

preeclampsia / endothelium dysfunction / cell proliferation / monolayer barrier function / nitric oxide

References

[1] ShahD.M.. Preeclampsia: new insights. Curr Opin Nephrol Hypertens, 2007, 16(3): 213-220

[2] MichielsC.. Endothelial cell functions. J Cell Physiol, 2003, 196(3): 430-443

[3] BaumwellS., KarumanchiS.A.. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract, 2007, 106(2): c72-81

[4] RabbaniM.L., RogersP.A.. Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. Reproduction, 2001, 122(1): 85-90

[5] LyallF., GreerI.A., BoswellF., et al.. Suppression of serum vascular endothelial growth factor immuno reactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol, 1997, 104(2): 223-228

[6] ReuvekampA., Velsing-AartsF.V., PoulinaI.E., et al.. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclam psia. Br J Obstet Gynaecol, 1999, 106(10): 1019-1022

[7] Cunningham FG, Gant NF, Leveno KJ, et al. Hypertensive disorders in pregnancy. In: Williams obstetrics: Common complications of pregnancy. 21th ed. Authorized reprinting by Science Press, 2002, 569–570

[8] FilleurS., CourtinA., Ait-Si-AliS., et al.. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogeni c thrombospondin-1 and slows tumor vascularization and growth. Cancer Res, 2003, 63(14): 3919-3922

[9] van Nieuw AmerongenG.P., VermeerM.A., Negre AminouP., et al.. Simvastatin improves disturbed end othelial barrier function. Circulation, 2000, 102(23): 2803-2809

[10] TaoJ., TuY.T., LiJ.W., et al.. Endogenous production of nitric oxide contributes to proliferation effect of vascular endothelial growth factor-induced malignant melanoma cell. Clin Exp Dermatol, 2006, 31(1): 94-99

[11] ZhangY., HeL., ZhouY.. Taspine isolated from Radix et Rhizoma Leonticis inhibits growth of human umbilical vein endothelial cell (HUVEC) by inducing its apoptosis. Phytomedicine, 2008, 15(1–2): 112-119

[12] LeungD.W., CachianesG., KuangW.J., et al.. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246(4935): 1306-1309

[13] ZiemerL.S., KochC.J., MaityA., et al.. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia, 2001, 3(6): 500-508

[14] LiuL.X., LuH., LuoY., et al.. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun, 2002, 291(4): 908-914

[15] MaynardS.E., MinJ.Y., MerchanJ., et al.. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertens ion, and proteinuria in preeclampsia. J Clin Invest, 2003, 111(5): 649-658

[16] TripathiR., RathG., JainA., et al.. Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. Ann Anat, 2008, 190(5): 477-489

[17] PolliottiB.M., FryA.G., SallerD.N., et al.. Second- trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol, 2003, 101(6): 1266-1274

[18] BussolatiB., DunkC., GrohmanM., et al.. Vascular endothelial growth factor receptor-1 modulates vascul ar endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol, 2001, 159(3): 993-1008

[19] KitamotoY., TakeyaM., TokunagaH., et al.. Glomerular endothelial cells are maintained by vascular endothel ial growth factor in the adult kidney. Tohoku J Exp Med, 2001, 195(1): 43-54

[20] SugimotoH., HamanoY., CharytanD., et al.. Neutrali zation of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem, 2003, 278(15): 12605-12608

[21] YangJ.C., HaworthL., SherryR.M., et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003, 349(253): 427-434

[22] KuenenB.C., LeviM., MeijersJ.C., et al.. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol, 2002, 22(9): 1500-1505

[23] GilbertJ.S., RyanM.J., LaMarcaB.B., et al.. Pathoph ysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol, 2008, 294: H541-550

[24] ZhuH., BunnH.F.. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol, 1999, 115(2): 239-247

[25] BanyaszI., SzaboS., BokodiG., et al.. Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol Hum Reprod, 2006, 12(4): 233-236